Geneva Partners LLC Cuts Stake in Eli Lilly and Company (NYSE:LLY)

Geneva Partners LLC lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 4.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,656 shares of the company’s stock after selling 428 shares during the quarter. Eli Lilly and Company makes up 2.8% of Geneva Partners LLC’s portfolio, making the stock its 12th biggest holding. Geneva Partners LLC’s holdings in Eli Lilly and Company were worth $5,046,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the business. Onyx Bridge Wealth Group LLC grew its position in shares of Eli Lilly and Company by 14.1% during the fourth quarter. Onyx Bridge Wealth Group LLC now owns 616 shares of the company’s stock worth $359,000 after purchasing an additional 76 shares in the last quarter. Wetzel Investment Advisors Inc. purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $5,588,000. Greenleaf Trust grew its position in shares of Eli Lilly and Company by 21.9% during the fourth quarter. Greenleaf Trust now owns 29,034 shares of the company’s stock worth $16,924,000 after purchasing an additional 5,210 shares in the last quarter. Naples Money Management LLC purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $257,000. Finally, Zhang Financial LLC grew its position in shares of Eli Lilly and Company by 2.1% during the fourth quarter. Zhang Financial LLC now owns 1,672 shares of the company’s stock worth $975,000 after purchasing an additional 34 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the sale, the insider now directly owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Trading Down 2.6 %

Shares of Eli Lilly and Company stock traded down $19.64 on Friday, reaching $726.31. The company had a trading volume of 3,486,055 shares, compared to its average volume of 3,073,465. The firm has a market cap of $690.11 billion, a price-to-earnings ratio of 125.23, a P/E/G ratio of 1.64 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The firm’s 50-day moving average price is $763.96 and its two-hundred day moving average price is $659.59. Eli Lilly and Company has a 1 year low of $369.76 and a 1 year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company’s quarterly revenue was up 28.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.09 EPS. As a group, research analysts predict that Eli Lilly and Company will post 12.52 earnings per share for the current fiscal year.

Analysts Set New Price Targets

LLY has been the subject of several research analyst reports. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Cantor Fitzgerald restated an “overweight” rating and set a $815.00 price target on shares of Eli Lilly and Company in a report on Monday. Morgan Stanley raised their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Bank of America raised their price target on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, March 1st. Finally, TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $728.05.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.